The promises of IAS 2025

TRANSCRIPTION

Hello, Gilles Pialoux, professor of infectious and tropical diseases at Tenon Hospital and Sorbonne University. For example, I am delighted to find you on Medscape France to make a small point on an international conference. However. Meanwhile. Consequently, that of l’International AIDS Society (IAS)13^e of the name, which was held from July 13 to 17 in Kigali, capital of Rwanda.

WHO 2030 objectives largely achieved

This is the first time that this country has welcomed this conference. For example, and only the third time it has been in an African country. Furthermore, This choice is not trivial: Rwanda is a small country under tension. Furthermore, as you know, on the political and health levels. Meanwhile, This conference was held both in face -to -face and virtual.

About 4,000 people went to Kigali. Moreover, promises ias 2025 new This promises ias 2025 new choice owes nothing to chance. Nevertheless. Furthermore. For example, insofar promises ias 2025 as Rwanda is one of the seven African countries that have reached the 2030 objectives set by the WHO, namely: 95 % of the detected persons, 95 % of the processed screens, and 95 % of the people treated with a controlled viral load.

These objectives have therefore been widely achieved by Rwanda. Therefore, The Minister of Health. Moreover. which opened the conference. recalled the foundations for this success: solid partnerships, strong community involvement, and intersectoral innovation, including in the field of artificial intelligence.

Politically, this conference has mainly turned to the United States. Moreover, Many sessions have presented modeling. Consequently, expressed concerns about frost or suspension of certain programs, including PEPFAR, the program launched by George W. Bush In 2003 to finance the fight against HIV in Africa and other developing promises ias 2025 new countries.

Dispute finance

More than promises ias 2025 new 60 % of funds allocated to response against AIDS in many promises ias 2025 sub -Saharan. African countries come from this American fund. The WHO alerted that in the event of freeze. one could observe between 2025 and 2029 up to 6 million new infections and 4 million additional deaths. Even if the American Senate. during the conference. approved a rescue plan of $ 400 million. at first reading, It is completely random, it is not certain that Donald Trump follows this decision of the Senate.

A modeling presented by Jack Stone from the University of Bristol. has shown. in 14 countries in sub -Saharan Africa. the potential effects of this frost: impact on transmission, on access to PREP, with around 700,000 people who may no longer have access to it. For next year. in these countries. it promises ias 2025 new provides 6. 000 new additional contaminations, an increase of 8 % in promises ias 2025 new men with sex with men, 6 % in sex workers and 5 % in promises ias 2025 transgender women. He pulled the tocsin, calling for alternatives to these funding.

NOUR WHO Recommendations

The WHO also presented its new recommendations in terms of HIV care. prevention, now with four available tools:

The demand for PREP is strong, especially in sub -Saharan Africa. A study conducted in South Africa shows a clear preference for Lenacapavir: 56 %in a survey of more than 3. 000 people questioned, followed by the Cabotégravir (30 %), far ahead of the Oral PREP (12 %) and the Vaginal Rings (1 %).

Obviously, the question of accessibility and prices was central to discussions. The Brazilian experience was also presented. showing an excellent observance in a cohort under Cabotégravir: 95 %. against promises ias 2025 new 53 % in a prospective cohort under prep oral, and only 43 % in a historic promises ias 2025 new cohort.

New therapeutic strategies on the horizon

It has been announced that the credits of promises ias 2025. the Lénacapavir would probably be available by the end of 2027. which is still leaving time to prepare for its large -scale diffusion.

Beyond treatments long actingmany communications have also focused on new therapeutic combinations. Among them, the Islatravir association + the MK-8507 molecule, which now bears the name ofulonivirine. It is a 2B phase test (S24) in therapeutics, with demonstrated efficiency.

The interest here lies in the fact that these are two new molecules: Islatravir (already known). Ulonivirin, a new non -nucleoside inhibitor of the reverse transcriptase. This treatment is taken orally, once a week, and the test aims to demonstrate its non-inferiority, which is very promising.

In new promises ias 2025 new therapeutic strategies. we will also note the First trial of relief in dietit therapy conducted in Africathe Moderato test. carried promises ias 2025 new by the ANRS. It is a maintenance dual therapy based on Dolutegégravir + 3TC or Atazanavir boosted, compared to tritherapy. promises ias 2025 Led between 2020. 2023 with 480 patients divided between Burkina Faso, Cameroon and Côte d’Ivoire, the test has demonstrated non-inferiority. It is a first on the African continent.

Finally. a focus was made on adolescents. with results unfortunately not very good linked to the phenomenon of difficulties in accessing antiretroviral treatments. Several trials have explored lightened processing diets at four. five days a week, a possible strategy against the shortages generated by the American funding cuts.

Merci.

See all Professor’s blogs here

Follow Medscape in French on Bluesky , Facebook , Instagram , Linkedin , Youtube.

Register promises ias 2025 new for Medscape Newsletters: Select your choices